Phase 2 Clinical Trial(Phase 2)
Clinical trials evaluating a drug's efficacy and optimal dosing in patients with the target disease.
Usage Examples
- The Phase 2 study demonstrated a statistically significant efficacy signal.
- Phase 2b results supported moving forward to pivotal trials.
- The dose selected for Phase 3 was based on Phase 2 efficacy and safety data.
What is Phase 2?
Phase 2 clinical trials evaluate whether a drug works in patients with the target disease and help determine the optimal dose and regimen. These studies typically enroll 100-500 patients and may be divided into Phase 2a (proof of concept, dose-finding) and Phase 2b (well-controlled efficacy studies).
Phase 2 studies assess preliminary efficacy signals, further characterize safety, refine the patient population, and identify biomarkers. They often use randomized, controlled designs and may be placebo-controlled or active-controlled.
Phase 2 results inform the design of pivotal Phase 3 trials, including dose selection, primary endpoints, and sample size calculations.
Regulatory Context
This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 312, ICH E8, ICH E9.
When This Matters
- The Phase 2 study demonstrated a statistically significant efficacy signal.
- Phase 2b results supported moving forward to pivotal trials.
- The dose selected for Phase 3 was based on Phase 2 efficacy and safety data.
Common Mistakes
- Applying one-region clinical assumptions to global submission strategies.
- Missing protocol-to-regulation traceability for pivotal studies.
- Underestimating how regional guidance updates impact trial documentation.
Related Regulations
Frequently Asked Questions
Phase 2a focuses on proof of concept and initial dose-finding in a small patient population. Phase 2b is larger, more rigorous, and aims to determine the optimal dose for Phase 3.
A seamless Phase 2/3 design combines dose selection and confirmatory efficacy evaluation in a single trial, using adaptive methods to select the best dose and continue enrollment into a Phase 3 portion.
Phase 2 trials typically enroll 100-500 patients, though this varies by indication, endpoints, and study design.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Track clinical trial regulations across global markets
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Related Regulatory Intelligence
Related Actions
Sources & References
